Cabometyx (cabozantinib) vs Retsevmo (selpercatinib)
Cabometyx (cabozantinib) vs Retsevmo (selpercatinib)
Cabometyx (cabozantinib) is a tyrosine kinase inhibitor that is primarily used in the treatment of advanced renal cell carcinoma, hepatocellular carcinoma, and medullary thyroid cancer, targeting multiple pathways involved in tumor growth. Retsevmo (selpercatinib), on the other hand, is a selective RET kinase inhibitor designed to treat cancers with RET alterations, such as RET fusion-positive non-small cell lung cancer, RET-mutant medullary thyroid cancer, and other thyroid cancers. When deciding between Cabometyx and Retsevmo, it is crucial to consider the specific genetic makeup of the cancer, as Retsevmo is particularly effective for cancers with RET gene alterations, while Cabometyx has a broader application for targeting various receptor tyrosine kinases in certain types of cancer.
Difference between Cabometyx and Retsevmo
| Metric | Cabometyx (cabozantinib) | Retsevmo (selpercatinib) |
|---|---|---|
| Generic name | Cabozantinib | Selpercatinib |
| Indications | Advanced renal cell carcinoma, hepatocellular carcinoma, medullary thyroid cancer | RET-altered thyroid cancers, non-small cell lung cancer |
| Mechanism of action | Tyrosine kinase inhibitor | RET kinase inhibitor |
| Brand names | Cabometyx | Retsevmo |
| Administrative route | Oral | Oral |
| Side effects | Diarrhea, fatigue, nausea, decreased appetite, hypertension, etc. | Dry mouth, fatigue, edema, hypertension, rash, etc. |
| Contraindications | None known | None known |
| Drug class | Tyrosine kinase inhibitor | Tyrosine kinase inhibitor |
| Manufacturer | Exelixis Inc. | Eli Lilly and Company |
Efficacy
Cabometyx (cabozantinib) in the Treatment of Thyroid Cancer
Cabometyx, which contains the active ingredient cabozantinib, is a medication that has shown efficacy in the treatment of certain types of thyroid cancer. Specifically, cabozantinib is approved for the treatment of progressive, metastatic medullary thyroid cancer (MTC). The efficacy of Cabometyx in treating MTC was demonstrated in a phase III clinical trial known as EXAM, which showed a significant increase in progression-free survival compared to placebo. Additionally, cabozantinib has been granted approval for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, indicating its broader anti-cancer activity.
In the context of differentiated thyroid cancer (DTC), cabozantinib has been evaluated in patients who are refractory to radioactive iodine therapy. The drug's efficacy in this setting is attributed to its ability to inhibit multiple tyrosine kinases involved in tumor growth and angiogenesis. Clinical trials have shown that cabozantinib can lead to partial responses and stable disease in a subset of patients with radioactive iodine-refractory DTC.
Retsevmo (selpercatinib) in the Treatment of Thyroid Cancer
Retsevmo, with the active ingredient selpercatinib, is a relatively new medication that has been shown to be effective in the treatment of thyroid cancers harboring specific genetic alterations. Selpercatinib is particularly indicated for the treatment of advanced or metastatic RET (rearranged during transfection) mutant medullary thyroid cancer (MTC) in patients who require systemic therapy. The drug has received accelerated approval based on the LIBRETTO-001 trial, which demonstrated robust antitumor activity, with a high response rate and durable responses in patients with RET-mutant MTC.
Furthermore, selpercatinib has shown efficacy in treating RET fusion-positive thyroid cancers, which include certain types of papillary and follicular thyroid cancers. The approval of Retsevmo for these indications is also based on the outcomes of the LIBRETTO-001 trial, where patients with RET fusion-positive thyroid cancers exhibited significant responses to the treatment. Selpercatinib's targeted approach allows for the selective inhibition of RET signaling, which is critical in the pathogenesis of these cancers.
Regulatory Agency Approvals
Cabometyx
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
Health Canada
-
Therapeutic Goods Administration (TGA), Australia
Retsevmo
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
Access Cabometyx or Retsevmo today
If Cabometyx or Retsevmo are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us